| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Reuben S Harris | Q88421845 |
| P2093 | author name string | Louis M Mansky | |
| Guylaine Haché | |||
| P433 | issue | 3 | |
| P921 | main subject | drug resistance | Q12147416 |
| P304 | page(s) | 148-157 | |
| P577 | publication date | 2006-07-01 | |
| P1433 | published in | AIDS Reviews | Q21042370 |
| P1476 | title | Human APOBEC3 proteins, retrovirus restriction, and HIV drug resistance | |
| P478 | volume | 8 |
| Q36387986 | A multi-scale mathematical modeling framework to investigate anti-viral therapeutic opportunities in targeting HIV-1 accessory proteins |
| Q40818553 | AID upmutants isolated using a high-throughput screen highlight the immunity/cancer balance limiting DNA deaminase activity |
| Q45324625 | APOBEC Enzymes as Targets for Virus and Cancer Therapy. |
| Q24618320 | APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis |
| Q36963205 | APOBEC3G cytosine deamination hotspots are defined by both sequence context and single-stranded DNA secondary structure |
| Q34211562 | APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenon |
| Q38394187 | APOBECs and virus restriction |
| Q35940059 | Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions |
| Q24672150 | Arginine methylation of the human immunodeficiency virus type 1 Tat protein by PRMT6 negatively affects Tat Interactions with both cyclin T1 and the Tat transactivation region |
| Q34416419 | Association of Potent Human Antiviral Cytidine Deaminases with 7SL RNA and Viral RNP in HIV-1 Virions |
| Q36945471 | Autonomous immunity in mucosal epithelial cells: fortifying the barrier against infection |
| Q28482052 | Characterization of the interaction of full-length HIV-1 Vif protein with its key regulator CBFβ and CRL5 E3 ubiquitin ligase components |
| Q24615552 | First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G |
| Q37073310 | Functional Upregulation of the DNA Cytosine Deaminase APOBEC3B by Polyomaviruses. |
| Q34120736 | Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure |
| Q34121572 | Identification of two APOBEC3F splice variants displaying HIV-1 antiviral activity and contrasting sensitivity to Vif |
| Q33815187 | Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics |
| Q33654949 | Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS. |
| Q28475150 | Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance |
| Q36019742 | Minimal Contribution of APOBEC3-Induced G-to-A Hypermutation to HIV-1 Recombination and Genetic Variation |
| Q46172691 | Molecular Interactions of a DNA Modifying Enzyme APOBEC3F Catalytic Domain with a Single-Stranded DNA. |
| Q26823568 | Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all |
| Q38928610 | N-linked glycosylation protects gammaretroviruses against deamination by APOBEC3 proteins |
| Q38879828 | Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections |
| Q38790689 | Reassessing APOBEC3G Inhibition by HIV-1 Vif-Derived Peptides |
| Q33419833 | Reassessing the role of APOBEC3G in human immunodeficiency virus type 1 infection of quiescent CD4+ T-cells |
| Q41868619 | Sequence editing by Apolipoprotein B RNA-editing catalytic component [corrected] and epidemiological surveillance of transmitted HIV-1 drug resistance |
| Q34488163 | Small-molecule APOBEC3G DNA cytosine deaminase inhibitors based on a 4-amino-1,2,4-triazole-3-thiol scaffold. |
| Q33300132 | T cells contain an RNase-insensitive inhibitor of APOBEC3G deaminase activity |
| Q26862780 | The APOBEC3 family of retroelement restriction factors |
Search more.